179 related articles for article (PubMed ID: 29961859)
1. Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis.
Colby DJ; Kroon E; Sacdalan C; Gandhi M; Grant RM; Phanuphak P; Ananworanich J; Robb ML; Phanuphak N
Clin Infect Dis; 2018 Aug; 67(6):962-964. PubMed ID: 29961859
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
[TBL] [Abstract][Full Text] [Related]
3. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
[TBL] [Abstract][Full Text] [Related]
4. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.
Knox DC; Anderson PL; Harrigan PR; Tan DH
N Engl J Med; 2017 Feb; 376(5):501-502. PubMed ID: 28146652
[No Abstract] [Full Text] [Related]
5. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
6. Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance.
Hsiao YY; Huang YC; Chang SY; Kuo CH; Chang SF; Lin YT; Luo YZ; Lee YL; Hung CC
J Microbiol Immunol Infect; 2021 Aug; 54(4):755-757. PubMed ID: 33597075
[No Abstract] [Full Text] [Related]
7. Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.
Anderson PL; Marzinke MA; Glidden DV
Clin Infect Dis; 2023 May; 76(10):1850-1853. PubMed ID: 36645796
[TBL] [Abstract][Full Text] [Related]
8. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
9. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
Thaden JT; Gandhi M; Okochi H; Hurt CB; McKellar MS
AIDS; 2018 Jun; 32(9):F1-F4. PubMed ID: 29683856
[TBL] [Abstract][Full Text] [Related]
10. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
[TBL] [Abstract][Full Text] [Related]
12. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
[TBL] [Abstract][Full Text] [Related]
13. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate.
Ruone S; Paxton L; McLaurin T; Taylor A; Hanson D; Heneine W; Brooks JT; García-Lerma JG
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):129-32. PubMed ID: 26689970
[TBL] [Abstract][Full Text] [Related]
15. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Curry SJ; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Jun; 321(22):2203-2213. PubMed ID: 31184747
[TBL] [Abstract][Full Text] [Related]
16. HIV Preexposure Prophylaxis: A Review.
Riddell J; Amico KR; Mayer KH
JAMA; 2018 Mar; 319(12):1261-1268. PubMed ID: 29584848
[TBL] [Abstract][Full Text] [Related]
17. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
18. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
Molina JM; Capitant C; Spire B; Pialoux G; Cotte L; Charreau I; Tremblay C; Le Gall JM; Cua E; Pasquet A; Raffi F; Pintado C; Chidiac C; Chas J; Charbonneau P; Delaugerre C; Suzan-Monti M; Loze B; Fonsart J; Peytavin G; Cheret A; Timsit J; Girard G; Lorente N; Préau M; Rooney JF; Wainberg MA; Thompson D; Rozenbaum W; Doré V; Marchand L; Simon MC; Etien N; Aboulker JP; Meyer L; Delfraissy JF;
N Engl J Med; 2015 Dec; 373(23):2237-46. PubMed ID: 26624850
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
[TBL] [Abstract][Full Text] [Related]
20. HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission.
Koole JC; de la Court F; Welkers MR; Yap K; Stalenhoef JE; Jurriaans S; de Vries HJ; Op de Coul EL; Prins M; Hoornenborg E
Euro Surveill; 2022 Apr; 27(14):. PubMed ID: 35393931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
